Peak Medical, ENvue’s Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® KitTYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription ...

Readers spotlight Monarch’s guest-first players club with seamless earn-and-redeem across Black Hawk and RenoDenver, CO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Momentum continues to build around Colorado’s gaming scene as Monarch Rewards placed #3 for the Best Player’s Club in Newsweek’s 2026 Readers’ Choice Awards, extending a run of national honors (AAA Four Diamond, Spa Monarch #2 in USA TODAY 10Best, and Wine Spectator Awards of Excellence) and reinforcing Monarch’s guest-first rewards model across both of i ...

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- M Split Corp. ("M Split") declares its monthly distribution of $0.03125 per share ($0.375 annually) for Class I Preferred shareholders and a monthly distribution of $0.03125 per share for Class II Preferred shareholders. The Class I Preferred share dividends are paid at an annual rate of 7.50% based on the $5 notional issue price. The Class II Preferred share dividends are paid at an annual rate of 7.50% based on the $5 notional issue price when the NAV exceeds $10 ...

Core Viewpoint - onsemi has entered a collaboration agreement with GlobalFoundries to develop and manufacture advanced gallium nitride (GaN) power devices, starting with 650V, to meet the increasing power demands in various high-growth markets [3][4][5] Group 1: Collaboration Details - The collaboration aims to combine onsemi's expertise in silicon drivers and controllers with GlobalFoundries' 200mm eMode GaN-on-silicon process to create high-performance GaN devices [3][4] - The partnership will focus on delivering optimized GaN devices for applications in AI data centers, electric vehicles, renewable energy, and aerospace, defense, and security [3][6] Group 2: Product Development and Applications - onsemi's GaN portfolio will include power supplies, DC-DC converters, onboard chargers, solar microinverters, energy storage systems, and motor drives, catering to the needs of high-density systems [6][7] - The collaboration is expected to accelerate the development of high-efficiency solutions and resilient supply chains for critical markets [5][6] Group 3: Technical Advantages - GaN technology allows for higher frequency operation, reducing component count and system size while improving efficiency and thermal performance [8] - Integrated functionality of GaN FETs with drivers and controllers in a single package enhances design cycles and reduces electromagnetic interference [9] Group 4: Timeline and Future Outlook - onsemi plans to begin sampling the new GaN devices in the first half of 2026, with a rapid scale-up to volume production anticipated thereafter [4][10]

Core Insights - Nordea Funds Ltd. has reduced its holding in Solar A/S, now owning 79,787,200 shares, which represents a 9.96% ownership stake following a sale on December 15, 2025 [1] Company Overview - Solar A/S is a leading European sourcing and services company focused on electrical, heating and plumbing, ventilation, climate, and energy solutions [2][3] - The company generated approximately DKK 12.2 billion in revenue in 2024 and employs around 2,900 people [3] - Solar A/S is listed on Nasdaq Copenhagen under the designation SOLAR B [3] Business Focus - The company emphasizes efficiency improvement and provides digital tools to enhance customer success [3] - Solar A/S is committed to driving the green transition and offers best-in-class solutions for sustainable resource use [3]

Core Insights - Actuate Therapeutics, Inc. announced that data from its Phase 2 study of elraglusib in metastatic pancreatic cancer will be presented at the 2026 ASCO GI Cancers Symposium [1] - The study evaluates elraglusib in combination with gemcitabine/nab-paclitaxel, a standard chemotherapy regimen for this type of cancer [1] Presentation Details - Oral Presentation: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma [2] - Date/Time: January 9, 2026, 4:15 PM-5:00 PM (PST) [2] - First Author: Devalingam Mahalingam, MD, PhD, Gastrointestinal Oncologist at Northwestern University [2] Poster Presentation - Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with elraglusib and gemcitabine/nab-paclitaxel [3] - Date/Time: January 9, 2026, 11:30 AM-1:00 PM; 5:00 PM-6:00 PM (PST) [4] - First Author: Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics [4] Company Overview - Actuate Therapeutics is focused on developing therapies for high-impact, difficult-to-treat cancers [4] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting pathways involved in tumor growth and resistance to conventional therapies [4]

• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz® and the RhodoLED® Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)• In addition, 19 international patent applications and/or registered designs for Rhodo ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The ...

Wins Orders for Copper Alloy Ingots and Aluminum Products, Demonstrating Strong Market Demand in the Asia-Pacific Region San Rafael, Bulacan, Philippines, Dec. 18, 2025 (GLOBE NEWSWIRE) -- One and one Green Technologies. INC (“One and one” or the “Company”) (NASDAQ: YDDL), a Philippines-based recycler holding a government-issued license to import and process hazardous waste as raw materials, today announced it has secured $7.7 million in contracts during November 2025 for its recycled metal products (the “N ...

RAM Activates Autonomous Detection, Voice Interaction, and Escalation Through SARA Detroit, Michigan, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions, along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced the launch of RAM, the ROSA™ Accessory Module, a new inline hardware platform designed to bring agentic AI capabilities to tens of mi ...